Neurogene (NGNE) Competitors $11.36 +0.47 (+4.32%) Closing price 04:00 PM EasternExtended Trading$11.50 +0.14 (+1.19%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NGNE vs. BCYC, KURA, URGN, MGTX, IMTX, ARVN, SION, CGEM, AKBA, and PRTCShould you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Bicycle Therapeutics (BCYC), Kura Oncology (KURA), UroGen Pharma (URGN), MeiraGTx (MGTX), Immatics (IMTX), Arvinas (ARVN), Sionna Therapeutics (SION), Cullinan Therapeutics (CGEM), Akebia Therapeutics (AKBA), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Neurogene vs. Bicycle Therapeutics Kura Oncology UroGen Pharma MeiraGTx Immatics Arvinas Sionna Therapeutics Cullinan Therapeutics Akebia Therapeutics PureTech Health Bicycle Therapeutics (NASDAQ:BCYC) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Do analysts recommend BCYC or NGNE? Bicycle Therapeutics currently has a consensus target price of $29.14, indicating a potential upside of 274.11%. Neurogene has a consensus target price of $47.20, indicating a potential upside of 315.49%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than Bicycle Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Neurogene 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Do institutionals and insiders believe in BCYC or NGNE? 86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by insiders. Comparatively, 9.9% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, BCYC or NGNE? Bicycle Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Does the MarketBeat Community prefer BCYC or NGNE? Bicycle Therapeutics received 113 more outperform votes than Neurogene when rated by MarketBeat users. However, 96.67% of users gave Neurogene an outperform vote while only 70.65% of users gave Bicycle Therapeutics an outperform vote. CompanyUnderperformOutperformBicycle TherapeuticsOutperform Votes14270.65% Underperform Votes5929.35% NeurogeneOutperform Votes2996.67% Underperform Votes13.33% Is BCYC or NGNE more profitable? Neurogene has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Neurogene's return on equity.Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics-450.64% -27.35% -20.81% Neurogene N/A -32.81%-27.96% Does the media refer more to BCYC or NGNE? In the previous week, Neurogene had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 6 mentions for Neurogene and 5 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.59 beat Neurogene's score of 0.11 indicating that Bicycle Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, BCYC or NGNE? Neurogene has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicycle Therapeutics$35.28M15.28-$180.66M-$2.88-2.70Neurogene$925K183.36-$36.32M-$4.27-2.66 SummaryNeurogene beats Bicycle Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NGNE vs. The Competition Export to ExcelMetricNeurogenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$169.61M$6.33B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-2.666.8221.8317.81Price / Sales183.36225.92379.4694.58Price / CashN/A65.6738.1534.64Price / Book0.785.866.454.00Net Income-$36.32M$141.86M$3.20B$247.23M7 Day Performance54.77%9.22%6.60%7.26%1 Month Performance-31.98%-12.42%-8.50%-6.26%1 Year Performance-69.65%-11.93%10.33%-0.18% Neurogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NGNENeurogene2.0917 of 5 stars$11.36+4.3%$47.20+315.5%-72.6%$169.61M$925,000.00-2.6690Analyst ForecastNews CoverageGap UpBCYCBicycle Therapeutics1.9077 of 5 stars$6.75-2.0%$29.14+331.7%-68.3%$467.11M$35.28M-2.05240KURAKura Oncology4.1624 of 5 stars$5.76-2.2%$25.50+342.7%-70.0%$465.15M$53.88M-2.44130URGNUroGen Pharma3.924 of 5 stars$9.96-2.8%$38.20+283.5%-29.8%$459.10M$90.40M-3.16200Positive NewsMGTXMeiraGTx4.5721 of 5 stars$5.75+1.2%$24.50+326.1%-1.4%$453.42M$33.28M-4.75300Gap UpHigh Trading VolumeIMTXImmatics2.3487 of 5 stars$3.68+5.1%$16.67+352.9%-60.1%$439.23M$155.84M-5.58260Short Interest ↓Gap DownHigh Trading VolumeARVNArvinas3.7044 of 5 stars$6.37-2.9%$35.50+457.3%-79.6%$438.08M$263.40M-2.30420Short Interest ↓High Trading VolumeSIONSionna TherapeuticsN/A$9.73-2.4%$38.50+295.7%N/A$429.33MN/A0.0035Gap DownCGEMCullinan Therapeutics2.3088 of 5 stars$7.25-2.2%$32.86+353.2%-53.6%$424.22MN/A-2.5530News CoveragePositive NewsGap DownAKBAAkebia Therapeutics3.4627 of 5 stars$1.77flat$6.50+267.2%+25.3%$418.13M$160.18M-7.70430Gap DownPRTCPureTech Health2.2396 of 5 stars$17.30flat$45.00+160.1%-38.3%$415.53M$3.33M0.00100Short Interest ↓Gap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies BCYC Alternatives KURA Alternatives URGN Alternatives MGTX Alternatives IMTX Alternatives ARVN Alternatives SION Alternatives CGEM Alternatives AKBA Alternatives PRTC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NGNE) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
